Dicerna Pharmaceuticals (DRNA) Downgraded by ValuEngine

ValuEngine lowered shares of Dicerna Pharmaceuticals (NASDAQ:DRNA) from a strong-buy rating to a buy rating in a research report report published on Monday.

A number of other equities analysts also recently issued reports on the company. BidaskClub downgraded Dicerna Pharmaceuticals from a buy rating to a hold rating in a research note on Friday, June 8th. HC Wainwright reiterated a hold rating and set a $14.00 price target on shares of Dicerna Pharmaceuticals in a research note on Tuesday, May 15th. Cowen reiterated a buy rating on shares of Dicerna Pharmaceuticals in a research note on Tuesday, April 24th. Evercore ISI reiterated an outperform rating and set a $17.00 price target (up previously from $14.00) on shares of Dicerna Pharmaceuticals in a research note on Friday, April 20th. Finally, B. Riley began coverage on Dicerna Pharmaceuticals in a research note on Wednesday, March 28th. They set a neutral rating and a $10.00 price target for the company. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company’s stock. The stock has an average rating of Hold and a consensus price target of $12.88.

Shares of DRNA opened at $13.26 on Monday. Dicerna Pharmaceuticals has a one year low of $2.69 and a one year high of $15.80.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last issued its earnings results on Monday, May 14th. The biopharmaceutical company reported ($0.30) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.87) by $0.57. The company had revenue of $1.55 million during the quarter, compared to the consensus estimate of $1.75 million. Dicerna Pharmaceuticals had a negative return on equity of 123.72% and a negative net margin of 1,665.11%. research analysts predict that Dicerna Pharmaceuticals will post -1.35 EPS for the current fiscal year.

In other Dicerna Pharmaceuticals news, insider James B. Weissman sold 10,000 shares of Dicerna Pharmaceuticals stock in a transaction that occurred on Wednesday, May 9th. The shares were sold at an average price of $15.00, for a total transaction of $150,000.00. Following the transaction, the insider now owns 19,800 shares of the company’s stock, valued at approximately $297,000. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider James B. Weissman sold 8,965 shares of Dicerna Pharmaceuticals stock in a transaction that occurred on Friday, April 20th. The stock was sold at an average price of $13.00, for a total transaction of $116,545.00. Following the transaction, the insider now directly owns 9,800 shares in the company, valued at approximately $127,400. The disclosure for this sale can be found here. 19.85% of the stock is currently owned by insiders.

Institutional investors have recently bought and sold shares of the business. Cubist Systematic Strategies LLC bought a new position in shares of Dicerna Pharmaceuticals during the 1st quarter worth approximately $102,000. Quantitative Systematic Strategies LLC bought a new position in shares of Dicerna Pharmaceuticals during the 1st quarter worth approximately $113,000. Caxton Corp bought a new position in shares of Dicerna Pharmaceuticals during the 1st quarter worth approximately $125,000. Jane Street Group LLC bought a new position in shares of Dicerna Pharmaceuticals during the 1st quarter worth approximately $136,000. Finally, Verition Fund Management LLC bought a new position in shares of Dicerna Pharmaceuticals during the 1st quarter worth approximately $141,000. 77.28% of the stock is currently owned by hedge funds and other institutional investors.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases. Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply